 In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi RASV strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects. 